Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Data and Analytics Tools Will Change the Medical Field

From altering the way patients experience their routine doctor visits to the way personal health will be monitored, the use of data analytics tools in the medical field is bound to bring change to the modern healthcare industry. Data analytics tools have been used across a wide range of industries in recent years. Companies ranging…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

From altering the way patients experience their routine doctor visits to the way personal health will be monitored, the use of data analytics tools in the medical field is bound to bring change to the modern healthcare industry.

Data analytics tools have been used across a wide range of industries in recent years. Companies ranging from video streaming services to major credit card providers have used data analysis tools to boost productivity and customer support.

With specialized software systems, these tools gather mass amounts of data and in turn draw conclusions from that information. These tools can be used to explain issues that multiple people seem to experience simultaneously while also preparing users how to be better prepared for what’s to come.

What this means for the healthcare system is a surge of health information that can be used across many fields to aid patients and benefit professionals of the medical field.

However, as many have seen throughout technological history, the thought of learning how to use new software can be unsettling. This can be especially difficult when it comes to patients attempting to maintain and understand their health through software they are unfamiliar with.

Director of USC-Brookings Schaeffer Initiative for Health Policy, Paul B. Ginsburg, Ph.D., who contributed to the works of “A Blueprint for the Future of AI” wants to assure people that data analytics will impact health care slowly and positively.

“People should not expect much change in their health care for quite a while,” stated Ginsburg.

He added that many barriers unique to healthcare patients mean that people do not need to worry about the healthcare system they have known for years undergoing extreme transformation overnight.

When asked about the changes people can expect to see, Ginsburg explained that while people will not see many changes in the way they experience their healthcare, they can expect to see changes with the quality of work from their physicians.

“People’s physicians are likely to be better equipped to provide effective care. They will be more informed about what approaches work best for a given patient and be better able to coordinate with other providers,” he said.

As technology becomes more prominent some people may become concerned that doctors will become obsolete in their roles as healthcare professionals. However, Ginsburg assured that there is no concern in the roles of doctors changing with their patients. Doctors will continue to be every bit as important to the healthcare industry.

Patients will continue to be in control of their personal health as well.

“Data analytics does not change doctors’ roles as the key decision maker—along with patients—in the health care system,” Ginsberg said.

He clarified that not only will doctors’ roles remain the same but they will in fact be better equipped to do their jobs due to this technological boost.

“Doctors will be better supported and will be able to deliver more effective care,” he noted.

Precision is of the utmost importance in the medical field. New software and data tools will ensure that patients receive optimal care, while professionals in the field will have more tools at their disposal to provide it.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512